Biotech Roundup: ASCO, BIO, Drug Setbacks, Incubators & More
Xconomy
JUNE 10, 2016
—If Jim Greenwood railing like King Lear in the storm isn’t entertaining enough, two notorious biotech characters have once again inspired the imagination of creative types. Ed Silverman at STAT reported the analyst note first. The new prices don’t reflect rebates and discounts.
67 
Let's personalize your content